WELIREG Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Welireg, and what generic alternatives are available?
Welireg is a drug marketed by Merck Sharp Dohme and is included in one NDA. There are two patents protecting this drug.
This drug has fifty-three patent family members in twenty-eight countries.
The generic ingredient in WELIREG is belzutifan. One supplier is listed for this compound. Additional details are available on the belzutifan profile page.
DrugPatentWatch® Generic Entry Outlook for Welireg
Welireg will be eligible for patent challenges on August 13, 2025. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be September 5, 2034. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for WELIREG?
- What are the global sales for WELIREG?
- What is Average Wholesale Price for WELIREG?
Summary for WELIREG
| International Patents: | 53 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 29 |
| Clinical Trials: | 3 |
| Patent Applications: | 33 |
| Drug Prices: | Drug price information for WELIREG |
| What excipients (inactive ingredients) are in WELIREG? | WELIREG excipients list |
| DailyMed Link: | WELIREG at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for WELIREG
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for WELIREG
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Merck Sharp & Dohme Corp. | Phase 1 |
| Peloton Therapeutics, Inc. | Phase 2 |
Pharmacology for WELIREG
| Drug Class | Hypoxia-inducible Factor Inhibitor |
| Mechanism of Action | Cytochrome P450 3A4 Inducers Hypoxia-inducible Factor 2 alpha Inhibitors |
US Patents and Regulatory Information for WELIREG
WELIREG is protected by four US patents and three FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of WELIREG is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting WELIREG
Aryl ethers and uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULT PATIENTS WITH VON HIPPEL-LINDAU DISEASE WHO REQUIRE THERAPY FOR ASSOCIATED RENAL CELL CARCINOMA, CENTRAL NERVOUS SYSTEM HEMANGIOBLASTOMAS, OR PANCREATIC NEUROENDOCRINE TUMORS, NOT REQUIRING IMMEDIATE SURGERY
Aryl ethers and uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULT PATIENTS WITH ADVANCED RENAL CELL CARCINOMA FOLLOWING A PROGRAMMED DEATH RECEPTOR-1 OR PROGRAMMED DEATH-LIGAND INHIBITOR AND A VASCULAR ENDOTHELIAL GROWTH FACTOR TYROSINE KINASE INHIBITOR
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULT PATIENTS WITH VON HIPPEL-LINDAU DISEASE WHO REQUIRE THERAPY FOR ASSOCIATED RENAL CELL CARCINOMA, CENTRAL NERVOUS SYSTEM HEMANGIOBLASTOMAS, OR PANCREATIC NEUROENDOCRINE TUMORS, NOT REQUIRING IMMEDIATE SURGERY
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF ADULT PATIENTS WITH ADVANCED RENAL CELL CARCINOMA FOLLOWING A PROGRAMMED DEATH RECEPTOR-1 OR PROGRAMMED DEATH-LIGAND INHIBITOR AND A VASCULAR ENDOTHELIAL GROWTH FACTOR TYROSINE KINASE INHIBITOR
FDA Regulatory Exclusivity protecting WELIREG
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
TREATMENT OF ADULT PATIENTS WITH ADVANCED RENAL CELL CARCINOMA FOLLOWING A PROGRAMMEDDEATH RECEPTOR-1 OR PROGRAMMED DEATH-LIGAND 1 INHIBITOR AND A VASCULAR ENDOTHELIAL GROWTH FACTOR TYROSINE KINASE INHIBITOR
Exclusivity Expiration: ⤷ Sign Up
TREATMENT OF ADULT PATIENTS WITH VON HIPPEL-LINDAU (VHL) DISEASE WHO REQUIRE THERAPY FOR ASSOCIATED RENAL CELL CARCINOMA (RCC), CENTRAL NERVOUS SYSTEM (CNS) HEMANGIOBLASTOMAS, OR PANCREATIC NEUROENDOCRINE TUMORS (PNET), NOT REQUIRING IMMEDIATE SURGERY
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck Sharp Dohme | WELIREG | belzutifan | TABLET;ORAL | 215383-001 | Aug 13, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Merck Sharp Dohme | WELIREG | belzutifan | TABLET;ORAL | 215383-001 | Aug 13, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Merck Sharp Dohme | WELIREG | belzutifan | TABLET;ORAL | 215383-001 | Aug 13, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Merck Sharp Dohme | WELIREG | belzutifan | TABLET;ORAL | 215383-001 | Aug 13, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Merck Sharp Dohme | WELIREG | belzutifan | TABLET;ORAL | 215383-001 | Aug 13, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for WELIREG
When does loss-of-exclusivity occur for WELIREG?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 7600
Patent: ÉTERES DE ARILO Y SUS USOS
Estimated Expiration: ⤷ Sign Up
Australia
Patent: 14318025
Patent: Aryl ethers and uses thereof
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 19397
Patent: ARYLETHERS ET UTILISATIONS DE CEUX-CI (ARYL ETHERS AND USES THEREOF)
Estimated Expiration: ⤷ Sign Up
China
Patent: 5530923
Patent: Aryl ethers and uses thereof
Estimated Expiration: ⤷ Sign Up
Patent: 0372550
Patent: 芳基醚及其用途 (Aryl ethers and uses thereof)
Estimated Expiration: ⤷ Sign Up
Croatia
Patent: 0191298
Estimated Expiration: ⤷ Sign Up
Patent: 0201701
Estimated Expiration: ⤷ Sign Up
Cuba
Patent: 385
Patent: COMPUESTOS ÉTERES DE ARILO ÚTILES PARA TRATAR CANCER DE CÉLULA RENAL
Estimated Expiration: ⤷ Sign Up
Patent: 160030
Patent: COMPUESTOS ÉTERES DE ARILO YÚTILES PARA TRATAR CANCER DE CÉLULA RENAL
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 23433
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 43784
Estimated Expiration: ⤷ Sign Up
Eurasian Patent Organization
Patent: 2124
Patent: АРИЛЭФИРЫ И ИХ ПРИМЕНЕНИЯ (ARYL ETHERS AND USES THEREOF)
Estimated Expiration: ⤷ Sign Up
Patent: 1690549
Patent: АРИЛЭФИРЫ И ИХ ПРИМЕНЕНИЯ
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 43784
Patent: ARYLÉTHERS ET UTILISATIONS DE CEUX-CI (ARYL ETHERS AND USES THEREOF)
Estimated Expiration: ⤷ Sign Up
Patent: 17851
Patent: ÉTHERS D'ARYLE ET LEURS UTILISATIONS (ARYL ETHERS AND USES THEREOF)
Estimated Expiration: ⤷ Sign Up
Patent: 17852
Patent: ÉTHERS D'ARYLE ET LEURS UTILISATIONS (ARYL ETHERS AND USES THEREOF)
Estimated Expiration: ⤷ Sign Up
Patent: 86835
Patent: ÉTHERS D'ARYLE ET LEURS UTILISATIONS (ARYL ETHERS AND USES THEREOF)
Estimated Expiration: ⤷ Sign Up
Hong Kong
Patent: 21667
Patent: 芳基醚及其用途 (ARYL ETHERS AND USES THEREOF)
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 45462
Estimated Expiration: ⤷ Sign Up
Patent: 52080
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 3888
Patent: אתרים אריליים ושימושים שלהם (Aryl ethers and uses thereof)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 86940
Estimated Expiration: ⤷ Sign Up
Patent: 46733
Estimated Expiration: ⤷ Sign Up
Patent: 18039
Estimated Expiration: ⤷ Sign Up
Patent: 16534134
Patent: アリールエーテルおよびその使用
Estimated Expiration: ⤷ Sign Up
Patent: 19070043
Patent: アリールエーテルおよびその使用 (ARYL ETHER AND USE THEREOF)
Estimated Expiration: ⤷ Sign Up
Patent: 19089855
Patent: アリールエーテルおよびその使用 (ARYL ETHER AND USE THEREOF)
Estimated Expiration: ⤷ Sign Up
Patent: 19089856
Patent: アリールエーテルおよびその使用 (ARYL ETHER AND USE THEREOF)
Estimated Expiration: ⤷ Sign Up
Lithuania
Patent: 43784
Estimated Expiration: ⤷ Sign Up
Patent: 17851
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 16002974
Patent: ETERES DE ARILO Y SUS USOS. (ARYL ETHERS AND USES THEREOF.)
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 6281
Patent: Aryl ethers and uses thereof
Estimated Expiration: ⤷ Sign Up
Peru
Patent: 160434
Patent: ETERES DE ARILO Y SUS USOS
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 43784
Estimated Expiration: ⤷ Sign Up
Patent: 17851
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 43784
Estimated Expiration: ⤷ Sign Up
Patent: 17851
Estimated Expiration: ⤷ Sign Up
Serbia
Patent: 960
Patent: ARIL ETRI I NJIHOVA PRIMENA (ARYL ETHERS AND USES THEREOF)
Estimated Expiration: ⤷ Sign Up
Patent: 953
Patent: ARIL ETRI I NJIHOVE UPOTREBE (ARYL ETHERS AND USES THEREOF)
Estimated Expiration: ⤷ Sign Up
Singapore
Patent: 201601616S
Patent: ARYL ETHERS AND USES THEREOF
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 43784
Estimated Expiration: ⤷ Sign Up
Patent: 17851
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 2153772
Estimated Expiration: ⤷ Sign Up
Patent: 160055199
Patent: 아릴 에테르 및 이의 용도 (ARYL ETHERS AND USES THEREOF)
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 39433
Estimated Expiration: ⤷ Sign Up
Patent: 84454
Estimated Expiration: ⤷ Sign Up
Patent: 23477
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 57071
Estimated Expiration: ⤷ Sign Up
Patent: 1605775
Patent: Aryl ethers and uses thereof
Estimated Expiration: ⤷ Sign Up
Patent: 1936572
Patent: Aryl ethers and uses thereof
Estimated Expiration: ⤷ Sign Up
Uruguay
Patent: 731
Patent: ÉTERES DE ARILO Y SUS USOS
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering WELIREG around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Cuba | 24385 | COMPUESTOS ÉTERES DE ARILO ÚTILES PARA TRATAR CANCER DE CÉLULA RENAL | ⤷ Sign Up |
| Lithuania | 3417851 | ⤷ Sign Up | |
| Japan | 2019089855 | アリールエーテルおよびその使用 (ARYL ETHER AND USE THEREOF) | ⤷ Sign Up |
| Mexico | 2016002974 | ETERES DE ARILO Y SUS USOS. (ARYL ETHERS AND USES THEREOF.) | ⤷ Sign Up |
| Hong Kong | 1221667 | 芳基醚及其用途 (ARYL ETHERS AND USES THEREOF) | ⤷ Sign Up |
| Spain | 2823477 | ⤷ Sign Up | |
| Spain | 2784454 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
